Latest Peptide News
Peptide News — page 2
FDA Unapproved GLP-1 Drugs Alert: What the Agency Is Warning About
The FDA refreshed its standing alert on unapproved GLP-1 drugs used for weight loss on September 1, 2026, restating why products sourced outside the approved supply chain carry risks the agency cannot vouch for. For anyone tracking a semaglutide or tirzepatide protocol, the practical question is where the product came from and what is actually on the label.
Weight Regain After Stopping Semaglutide Mapped in New Meta-Analysis
A reconstructed aggregate-data meta-analysis published in Endocrinology, Diabetes & Metabolism models weight regain after stopping semaglutide or tirzepatide, and it landed the same week as a separate analysis of glycaemic changes after semaglutide discontinuation in type 1 diabetes. Together they sharpen a question that matters to anyone on a GLP-1 protocol: what happens when the injections stop.
CagriSema Phase 3 Trials Expand Into Children and a New Dose Comparison
ClinicalTrials.gov records reviewed on August 31, 2026 show the CagriSema phase 3 trials program has widened to include adolescents and a head-to-head comparison of two CagriSema dose levels against semaglutide alone. For anyone already tracking a semaglutide protocol, this is the clearest signal yet of what the next generation of injectable obesity medicines is being tested to do.
Retatrutide Diabetic Ketoacidosis Case Report Involves Online Source
A single-patient report newly indexed in PubMed describes retatrutide diabetic ketoacidosis risk in a type 1 diabetes patient who bought the investigational drug online while also fighting a bacterial gut infection. It is the kind of case that surfaces when an unapproved molecule circulates faster than its clinical evidence.
Semaglutide heart effects: new cardiac CT and tissue studies
A cluster of new peer-reviewed publications shifts attention from weight and glucose toward semaglutide heart effects — specifically cardiac structure, gene expression in human heart tissue, and cardiovascular outcomes in people with diabetes and existing vascular or kidney disease. None of them changes how anyone takes the drug, but together they show where the research is heading.
Semaglutide Opioid Use Disorder Trial Opens Phase 2 Enrollment
A Phase 2 semaglutide opioid use disorder trial is now recruiting 200 adults in outpatient addiction treatment, testing whether the GLP-1 receptor agonist helps people refrain from illicit opioids. It is one of two new GLP-1 trials registered this week that push these drugs well outside diabetes and weight management.
Semaglutide Muscle Loss Study Joins New Trials on Lean Mass
Three separate research entries indexed in the past week — a longitudinal semaglutide muscle loss study, a review of skeletal muscle health during incretin-based therapy, and a newly posted Phase 4 trial — all converge on the same unanswered question. For anyone tracking a GLP-1 protocol, lean mass is moving from forum speculation to formal endpoint.
Synthetic Semaglutide Claims Challenged Over Reporting Gaps
A newly indexed letter in Diabetes, Obesity & Metabolism takes aim at the evidence behind synthetic semaglutide used for weight management, arguing that reporting gaps make the clinical claims hard to evaluate. For anyone tracking a compounded or non-brand GLP-1 protocol, the argument is about what you can and cannot infer from a study that says the molecule is the same.
Retatrutide Cardiovascular Outcomes Trial Reaches Full Enrollment
The registry entry for TRIUMPH-Outcomes, the phase 3 retatrutide cardiovascular outcomes trial, was updated on August 24 to show the study active and closed to new participants. It is the largest single trial in Eli Lilly's retatrutide program and the one that will decide whether the triple agonist can claim organ-protection benefits rather than weight loss alone.
GLP-1 Non-Responders: New Review Asks If Response Can Be Predicted
A review indexed this month in Diabetes, Obesity & Metabolism takes on one of the least discussed features of incretin therapy: the substantial minority of people who get far less from it than trial averages suggest. Alongside new subgroup work on tirzepatide in women with polycystic ovary syndrome and a paper on muscle mass during incretin-based weight loss, the question of what separates GLP-1 non-responders from responders is moving from anecdote to research agenda.
Semaglutide cognitive side effects: 13,007-patient BMJ study
Three peer-reviewed papers examining semaglutide cognitive side effects and broader neuropsychiatric signals from GLP-1 receptor agonists were indexed within days of each other. The largest is a retrospective cohort of 13,007 people in the United States who already carried a psychiatric diagnosis.
Retatrutide Phase 3 Trial Completed in 2,335-Person Obesity Study
A ClinicalTrials.gov record updated August 21, 2026 shows Eli Lilly's largest registered retatrutide phase 3 trial completed after enrolling 2,335 participants with obesity or overweight. No outcome data has been posted to the registry yet, and retatrutide remains an investigational drug with no marketing approval anywhere.